You searched for side effects - Page 69 of 311 - Medivizor
Navigation Menu

Can a nanoparticle-based paclitaxel be more effective than a standard-preparation paclitaxel in the treatment of advanced non-small cell lung cancer?

Can a nanoparticle-based paclitaxel be more effective than a standard-preparation paclitaxel in the treatment of advanced non-small cell lung cancer?

Posted by on Jan 19, 2021 in Lung cancer | 0 comments

In a nutshell This trial compared the use of standard paclitaxel (SP; Taxol) versus a new nanoparticle micellar preparation of paclitaxel (NmP) as a first-line treatment for non-small cell lung cancer (NSCLC). The authors found that NmP had better effectiveness and safety in treating NSCLC than SP.  Some...

Read More

Evaluating barberry supplements for hypertension

Evaluating barberry supplements for hypertension

Posted by on Jan 17, 2021 in Hypertension | 0 comments

In a nutshell This clinical trial looked at the effect of barberry on patients with high blood pressure. It found that barberry increased arteries’ flexibility and reduced inflammation. Some background As the heart pumps blood, the arteries expand and contract to accommodate the changing volume of blood and maintain a steady blood pressure. When...

Read More

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Posted by on Jan 17, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of GDP (gemcitabine, dexamethasone, and cisplatin) and ICE (ifosfamide, carboplatin, and etoposide) regimens as salvage therapy in patients with relapsed/refractory aggressive lymphoma. The data showed that both the GDP and ICE regimens are suitable options for relapsed/refractory...

Read More

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Comparing the GDP and ICE regimens as salvage treatment for relapsed/refractory aggressive lymphoma

Posted by on Jan 17, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of GDP (gemcitabine, dexamethasone, and cisplatin) and ICE (ifosfamide, carboplatin, and etoposide) regimens as salvage therapy in patients with relapsed/refractory aggressive lymphoma. The data showed that both the GDP and ICE regimens are suitable options for relapsed/refractory...

Read More

Total body irradiation vs chemotherapy conditioning in children with acute lymphoblastic leukemia

Total body irradiation vs chemotherapy conditioning in children with acute lymphoblastic leukemia

Posted by on Jan 17, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if chemotherapy (CT) conditioning could replace total body irradiation (TBI) before stem cell transplant (SCT) in children with acute lymphoblastic leukemia (ALL).  This study concluded that TBI in combination with CT was safer and more effective than CT conditioning alone in these...

Read More

Evaluating erlotinib plus radiotherapy for stage 3, EGFR-positive non-small cell lung cancer that cannot be surgically removed

Evaluating erlotinib plus radiotherapy for stage 3, EGFR-positive non-small cell lung cancer that cannot be surgically removed

Posted by on Jan 17, 2021 in Lung cancer | 0 comments

In a nutshell This trial was carried to look at the use of erlotinib (Tarceva) with radiotherapy (RT) compared to standard treatment for EGFR-positive non-small cell lung cancer (NSCLC) that cannot be removed surgically. The authors found that erlotinib and RT improved survival without cancer worsening in these patients. Some...

Read More

Does continuous nivolumab improve outcomes in advanced non-small cell lung cancer?

Does continuous nivolumab improve outcomes in advanced non-small cell lung cancer?

Posted by on Jan 10, 2021 in Lung cancer | 0 comments

In a nutshell This study compared 1-year fixed-duration versus continuous nivolumab (Opdivo) for the treatment of previously treated advanced non-small-cell lung cancer (NSCLC). The authors found that continuing nivolumab beyond a fixed duration of 1-year may improve patient outcomes.  Some background NSCLC is the most common form of lung cancer....

Read More

Is PEX168 alone effective in improving blood glucose control in patients with type 2 diabetes?

Is PEX168 alone effective in improving blood glucose control in patients with type 2 diabetes?

Posted by on Jan 10, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study looked at the effect of treatment with polyethylene glycol loxenatide (PEX168) alone in patients with poorly controlled type 2 diabetes (T2D). They found that PEX168 significantly improved blood glucose control in these patients. Some background Blood glucose is controlled by many hormones. The most...

Read More

Pembrolizumab as a treatment for advanced colorectal cancer predisposed to mutations.

Pembrolizumab as a treatment for advanced colorectal cancer predisposed to mutations.

Posted by on Jan 10, 2021 in Colorectal cancer | 0 comments

In a nutshell This study compared the use of pembrolizumab (Keytruda) to chemotherapy for the treatment of patients with colorectal cancer (CRC) and high microsatellite instability (MI). This study showed that patients who received pembrolizumab had a better outcome than those who were given chemotherapy. Some background Patients who are...

Read More

Colorectal cancer treatment with regorafenib and trifluridine/tipiracil: A comparison

Colorectal cancer treatment with regorafenib and trifluridine/tipiracil: A comparison

Posted by on Jan 10, 2021 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness of regorafenib (Stivarga), trifluridine/tipiracil (TFTP; Lonsurf), and combinations of these drugs in the treatment of patients with inoperable colorectal cancer. Researchers suggested that a combination of TFTP and regorafenib is associated with longer survival and fewer side effects. Some...

Read More